Tang Capital Entities File Schedule 13G for Crescent Biopharma

Tang Capital Management, LLC, along with related entities and Kevin Tang, filed a Schedule 13G with the SEC, reporting beneficial ownership of 700,000 ordinary shares of Crescent Biopharma, Inc., representing 5.04% of the outstanding shares. The filing includes Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. The shares are held with shared voting and dispositive power among the entities and Kevin Tang. The filing is made pursuant to Rule 13d-1(c) and includes a joint filing agreement.